During the past 25 years, the arsenal of drugs to combat HIV-1 infection has increased continuously, even though most anti-HIV-1 drugs experienced clinical failure due to antiretroviral drug resistance resulting from mutations in HIV-1 protein targets. Therefore, a medical need in this field is still felt, and additional conserved drug targets need to be explored to achieve virus suppression in drug-experienced patients or patients infected with drug-resistant viruses. In this context, the Nucleocapsid protein 7 (NCp7) is considered a strongly profitable drug target as it is a highly conserved protein in several HIV-1 subtypes that plays a central role in virus replication, and whose inhibition could interfere with multiple steps in the HIV...
Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency virus (HIV) e...
As a key structural protein, HIV capsid (CA) protein plays multiple roles in the HIV life cycle, and...
The currently available anti-HIV-1 therapeutics is highly beneficial to infected patients. However, ...
Nucleocapsid protein 7 (NCp7) represents a viable target not yet reached by the currently available ...
This thesis work is devoted to the study of potential antiviral drugs to fight the human immunodefic...
In the present work, we described the design, synthesis and biological evaluation of a novel series ...
In recent years, the use of FDA approved Highly Active Antiretroviral Therapies (HAARTs) has shown g...
The HIV-1 nucleocapsid (NC) protein is a small basic DNA and RNA binding protein that is absolutely ...
International audienceHIV/AIDS is still one of the leading causes of death worldwide. Current drugs ...
The interest in the synthesis of Se-containing compounds is growing with the discovery of derivative...
The nucleocapsid protein (NC) is a highly conserved protein in diverse HIV-1 subtypes that plays a c...
Due to its essential roles in the viral replication cycle and to its highly conserved sequence, the ...
The HIV-1 nucleocapsid protein (NCp7) is an emerging target for antiretroviral therapy. Five hits ha...
HIV/AIDS is still one of the leading causes of death worldwide. Current drugs that target the canoni...
Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency virus (HIV) e...
As a key structural protein, HIV capsid (CA) protein plays multiple roles in the HIV life cycle, and...
The currently available anti-HIV-1 therapeutics is highly beneficial to infected patients. However, ...
Nucleocapsid protein 7 (NCp7) represents a viable target not yet reached by the currently available ...
This thesis work is devoted to the study of potential antiviral drugs to fight the human immunodefic...
In the present work, we described the design, synthesis and biological evaluation of a novel series ...
In recent years, the use of FDA approved Highly Active Antiretroviral Therapies (HAARTs) has shown g...
The HIV-1 nucleocapsid (NC) protein is a small basic DNA and RNA binding protein that is absolutely ...
International audienceHIV/AIDS is still one of the leading causes of death worldwide. Current drugs ...
The interest in the synthesis of Se-containing compounds is growing with the discovery of derivative...
The nucleocapsid protein (NC) is a highly conserved protein in diverse HIV-1 subtypes that plays a c...
Due to its essential roles in the viral replication cycle and to its highly conserved sequence, the ...
The HIV-1 nucleocapsid protein (NCp7) is an emerging target for antiretroviral therapy. Five hits ha...
HIV/AIDS is still one of the leading causes of death worldwide. Current drugs that target the canoni...
Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency virus (HIV) e...
As a key structural protein, HIV capsid (CA) protein plays multiple roles in the HIV life cycle, and...
The currently available anti-HIV-1 therapeutics is highly beneficial to infected patients. However, ...